IMITREX tablet drug interactions: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 12: | Line 12: | ||
MAO‑A inhibitors increase systemic exposure by 7-fold. Therefore, the use of IMITREX Tablets in patients receiving MAO‑A inhibitors is contraindicated [see Clinical Pharmacology (12.3)]. | MAO‑A inhibitors increase systemic exposure by 7-fold. Therefore, the use of IMITREX Tablets in patients receiving MAO‑A inhibitors is contraindicated [see Clinical Pharmacology (12.3)]. | ||
====Other 5-HT1 Agonists==== | ====Other 5-HT1 Agonists==== | ||
Because their vasospastic effects may be additive, co-administration of IMITREX Tablets and other 5‑HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated. | Because their vasospastic effects may be additive, co-administration of IMITREX Tablets and other 5‑HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated. | ||
====Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome==== | ====Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome==== | ||
Latest revision as of 08:03, 1 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Drug Interactions
Ergot-Containing Drugs
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and IMITREX Tablets within 24 hours of each other is contraindicated.
Monoamine Oxidase-A Inhibitors
MAO‑A inhibitors increase systemic exposure by 7-fold. Therefore, the use of IMITREX Tablets in patients receiving MAO‑A inhibitors is contraindicated [see Clinical Pharmacology (12.3)].
Other 5-HT1 Agonists
Because their vasospastic effects may be additive, co-administration of IMITREX Tablets and other 5‑HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated.
Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome
Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)].[1]
References
Adapted from the FDA Package Insert.